Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Commentary

Role of regulatory T cells in experimental arthritis and implications for clinical use

Marco Londei

Author affiliations

Institute of Child Health, University College London, London, UK

Citation and License

Arthritis Research & Therapy 2005, 7:118-120  doi:10.1186/ar1745

Published: 7 April 2005

Abstract

CD4+CD25+ T regulatory cells are avidly studied because they modulate immune responses. Their possible role in autoimmunity and more specifically in rheumatoid arthritis (RA) has been highlighted by a string of reports, one of which is in the last issue of Arthritis Research & Therapy. There are, however, key questions that have not yet been addressed before their use can be considered as a real therapeutic option. The first is the actual, in a clinical setting, efficacy of Treg to treat active chronic autoimmune diseases such as RA. The second is how we can practically deliver their therapeutic activity in patients. Once these points have been addressed we will have a new and potentially very effective 'magic bullet' for the treatment of chronic autoimmune diseases.